X

Journal of Clinical Oncology

Journal of Clinical Oncology
HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer

The multicenter VARIANZ study aims to investigate the background of response and resistance to trastuzumab in mGC.

Journal of Clinical Oncology
03/25/2021
Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL

Study investigators conduct a phase I trial of autologous CD19.28ζ-CAR T cells in CAYAs with relapsed or refractory B-ALL.

Journal of Clinical Oncology
03/25/2021
Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectom

The primary aim of the B-43 trial is to assess the efficacy of RT alone vs concurrent RT plus T in preventing recurrence of ipsilateral breast cancer in women with ductal carcinoma in situ.

Journal of Clinical Oncology
03/19/2021
Favorable Trisomies and ETV6-RUNX1 Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331

COG AALL0331 tests whether pegaspargase intensification on a low-intensity chemotherapy backbone would improve the CCR rate in a low-risk subset of children with standard-risk B-ALL.

Journal of Clinical Oncology
03/19/2021
Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer

CheckMate 451, a double-blind phase III trial, evaluated nivolumab plus ipilimumab and nivolumab monotherapy as maintenance therapy following first-line chemotherapy for ED-SCLC.

Journal of Clinical Oncology
03/08/2021
A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma

The goal of this study is to compare lenalidomide plus R-CHOP (R2-CHOP) with placebo/R-CHOP in previously untreated, ABC-type DLBCL.

Journal of Clinical Oncology
02/23/2021
Impact of Organ Function–Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma

Exclusion of patients needing urgent treatment or requiring novel biomarkers before enrollment has impacted the ability to enroll real-world patients in frontline trials of DLBCL.

Journal of Clinical Oncology
Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%

Pembrolizumab monotherapy is standard first-line therapy for metastatic NSCLC with programmed death ligand 1 tumor proportion score ≥ 50% without actionable driver mutations.

Journal of Clinical Oncology
Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD

Severe AGVHD is a major cause of death after unrelated-donor hematopoietic cell transplant, resulting in particularly high mortality after HLA-mismatched transplantation.

Journal of Clinical Oncology
01/15/2021
Duration of Adjuvant Doublet Chemotherapy in Patients With High-Risk Stage II Colorectal Cancer

As oxaliplatin results in cumulative neurotoxicity, reducing treatment duration without loss of efficacy would benefit patients and healthcare providers.

 

Journal of Clinical Oncology
01/13/2021
Subscribe to Journal of Clinical Oncology

source list reference

#7d60d9
#2694a4
#32a887
#85eb24
#352625
#4d4537
#d2093c
#8e3f1c
#76b6c3
#bfcfc8
#c61417
#67e25b
#efef71
#03cffc
#42fc9a
#cc529a
#c59445
#c8cc0c
#bf6be3
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
#a153ac
#e7f6e3
#9a8c2c
#a9c507
#2b9ab3
#e61923
#990677
#4a7bab
#89f67c
#49a21d
#2c990a
#d7da81
#575662
#a60538
#49cde9
#c20fce
#d95d39